Navigating the Growth of North America NGS Automation Market: Key Insights and Market Forecasts to 2030 Meticulous Research®, a leading global market research company, has published a comprehensive report on the North American Next-Generation Sequencing (NGS) Automation Market. The report, titled North America NGS Automation Market by Product (Workstations, Consumables), Sequencing Type (Whole Genome, Exome, Targeted Genome), Application (Drug Discovery, Diagnostics, Oncology), End User (Hospitals, Pharmaceutical, Diagnostic Labs) - Forecast to 2030, provides a thorough analysis of market trends, growth drivers, challenges, and opportunities in the region. Download Sample Research PDF @ https://www.meticulousresearch.com/download-samplereport/cp_id=5736 Market Overview and Forecast According to this latest publication, the North American NGS automation market is projected to experience robust growth, registering a Compound Annual Growth Rate (CAGR) of 14% from 2024 to 2030. This growth is expected to propel the market's value to an estimated $776.1 million by 2030. Several factors are driving this expansion, including the increasing prevalence of cancer, rising demand for NGS automation in laboratories, and the growing need for more efficient and streamlined workflows in clinical and research settings. One of the key drivers of growth in the market is the rising demand for NGS automation in laboratory environments. NGS has emerged as a critical tool for genetic sequencing and diagnostics, with automation playing an essential role in improving efficiency, accuracy, and scalability. Laboratories are increasingly adopting automated platforms to optimize workflows, minimize manual errors, and reduce labor costs associated with sequencing processes. These advancements allow researchers and clinicians to focus on more complex aspects of genomic analysis and discovery, enhancing overall productivity and reducing the time required to generate results. Additionally, substantial investments in pharmaceutical research and development (R&D), along with increased healthcare expenditures, are contributing to the market's expansion. As the demand for personalized medicine and targeted therapies grows, the need for high-throughput sequencing technologies to support drug discovery and diagnostics has surged. The growing application of NGS technology in various fields, particularly in oncology, reproductive health, and infectious diseases, is expected to create vast opportunities for further market growth. Collaborations between NGS technology vendors to develop more advanced library preparation protocols are also contributing to market development. These efforts are designed to improve
the quality and efficiency of NGS-based analyses, driving demand for more sophisticated and reliable automation solutions. However, despite the market’s promising outlook, several challenges may hinder its full potential. The high upfront costs associated with NGS automation platforms, such as workstations and robotic systems, are a significant barrier for smaller laboratories and institutions. These high costs may limit the adoption of automation technologies, particularly in developing regions or smaller healthcare providers that are operating under tight budget constraints. Nevertheless, as technological advancements reduce the cost of automation and enhance the scalability of these systems, the market is expected to experience wider adoption in the coming years. Market Segmentation and Insights The North American NGS automation market is segmented by several key factors, including product type, sequencing type, application, end-user, and country. Each segment plays a crucial role in shaping the market's future dynamics and growth potential. Browse In Depth: https://www.meticulousresearch.com/product/north-america-ngsautomation-market-5736 Product Type The product segment of the market is divided into two main categories: workstations/robotic platforms and reagents/consumables. Among these, the workstations/robotic platforms segment is expected to capture the largest share of the market in 2024. This is primarily due to the benefits offered by automated workstations in library preparation processes, such as increased efficiency, faster turnaround times, reduced per-sample costs, and improved reproducibility compared to manual methods. These advantages make NGS automation workstations highly desirable for pharmaceutical and biotechnology companies, which rely on high-throughput sequencing for drug discovery and genetic research. Automated systems not only enhance the speed of data acquisition but also enable high-volume sequencing without compromising quality, making them indispensable tools in drug development and clinical diagnostics. As pharmaceutical and biotechnology companies continue to invest heavily in R&D, demand for such automated platforms is expected to remain strong. Sequencing Type The sequencing type segment in the report includes whole genome sequencing, whole exome sequencing, targeted genome sequencing, and other sequencing types. Whole genome sequencing (WGS) is anticipated to capture the largest share of the market due to its increasing utilization in identifying novel drug targets and advancing therapeutic techniques. WGS enables
comprehensive genetic analyses, making it an essential tool for developing targeted therapies, gene therapies, and oligonucleotide-based treatments. The demand for whole genome sequencing is driven by its ability to provide a more complete view of genetic variations, which is crucial for the discovery of biomarkers for diseases, particularly cancer. The application of WGS in oncology is gaining significant momentum, as it allows researchers to pinpoint specific genetic mutations that may be responsible for the onset of various cancers, leading to more effective and personalized treatment options. Application The application segment of the NGS automation market includes drug discovery, clinical diagnostics (such as oncology diagnostics, reproductive health diagnostics, and infectious disease diagnostics), and other applications. In 2024, the drug discovery segment is expected to dominate the market. NGS technologies have become pivotal in identifying genetic mutations associated with diseases, enabling pharmaceutical companies to develop targeted treatments and therapies for previously underserved patient populations. NGS is increasingly used in drug discovery to identify new biomarkers, assess genetic variability, and develop personalized medicine strategies. As the pharmaceutical industry continues to focus on precision medicine, the demand for NGS technologies to support these efforts will likely expand. Additionally, the increasing adoption of NGS in clinical diagnostics for conditions such as cancer, genetic disorders, and infectious diseases will further contribute to the growth of this segment. End User The end-user segment includes pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, academic and research institutes, and other end users. In 2024, pharmaceutical and biotechnology companies are expected to hold the largest share of the market. This dominance is attributed to the increasing investment in R&D and the growing emphasis on genetic-based drug development. Pharmaceutical companies are leveraging NGS automation technologies to accelerate the discovery of novel drug candidates and develop more effective treatments based on genetic insights. Country Geographically, the report covers the North American market, with a focus on the U.S., Canada, and Mexico. Among these countries, the U.S. is expected to account for the largest share of the market in 2024. The U.S. market is driven by several factors, including high levels of R&D investment in the pharmaceutical and biotechnology sectors, the presence of leading NGS automation platform providers, and favorable government initiatives supporting genomics
research. Additionally, the increasing prevalence of cancer and other genetic diseases, along with growing public awareness of NGS-based testing, contributes to the market's expansion. Government support for genomics research, such as funding for the Precision Medicine Initiative, has further accelerated the adoption of NGS technologies in the U.S. The country also boasts a favorable reimbursement scenario for NGS-based tests, which has further boosted the demand for these technologies in clinical settings. Key Players in the Market The North American NGS automation market is highly competitive, with several key players driving innovation and shaping the market landscape. These include: •
Agilent Technologies, Inc. (U.S.)
•
Danaher Corporation (U.S.)
•
Eppendorf AG (Germany)
•
Hamilton Company (U.S.)
•
PerkinElmer, Inc. (U.S.)
•
Tecan Group Ltd. (Switzerland)
•
BRAND GMBH + CO KG (Germany)
•
Hudson Robotics (U.S.)
•
SPT Labtech (U.K.)
•
Thermo Fisher Scientific Inc. (U.S.)
•
F. Hoffmann-La Roche Ltd. (Switzerland)
These companies are at the forefront of developing advanced NGS automation platforms and reagents that improve the efficiency and reliability of genomic analyses. Strategic partnerships, mergers and acquisitions, and ongoing R&D are expected to intensify competition in the coming years, further driving market growth and innovation. Quick Buy – North America NGS Automation Market – Global Opportunity Analysis and Industry Forecast (2024-2030), Research Report: https://www.meticulousresearch.com/Checkout/75503538 Conclusion
The North American NGS automation market is poised for significant growth in the coming years, driven by the increasing prevalence of cancer, the rising demand for efficient laboratory workflows, and ongoing advancements in genomic research. As NGS technology continues to evolve and become more accessible, automation will play a critical role in enhancing the speed, accuracy, and scalability of genetic analyses. The market presents numerous opportunities for both established players and new entrants to capitalize on the growing demand for high-quality, automated NGS solutions. Despite some challenges, including high equipment costs, the overall outlook for the North American NGS automation market remains optimistic, with the U.S. continuing to lead the way in adoption and innovation. Contact Us: Meticulous Research® Email-
[email protected] Contact Sales- +1-646-781-8004 Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
